Jemperli
Understanding Jemperli®
Jemperli® (dostarlimab-gxly) is a monoclonal antibody that targets PD-1 (programmed death-1), a protein that helps cancer cells evade the immune system. By blocking PD-1, Jemperli® enables the immune system to better recognize and attack cancer cells. It is primarily used for treating certain types of endometrial and solid tumors characterized by DNA mismatch repair deficiencies (dMMR).
How Jemperli® Works:
- Inhibits PD-1, allowing immune cells to detect and attack tumors
- Effective for dMMR cancers, which have defects in DNA repair mechanisms
- Can be used as monotherapy or in combination with chemotherapy
FDA Approvals:
- April 22, 2021: Approved for dMMR recurrent or advanced endometrial cancer
- August 17, 2021: Approved for any dMMR solid tumors
- July 31, 2023: Approved as first-line therapy for dMMR advanced/recurrent endometrial cancer (in combination with chemotherapy)
For more information, please visit the Jemperli® patient website and speak with your healthcare provider to determine if Jemperli® is the right treatment option for you.
Referral Form: |
WHAT IT TREATS: |
MANUFACTURER: GlaxoSmithKline (GSK) |
CLASS: PD-1 Inhibitor (Immune Checkpoint Inhibitor)
Monoclonal Antibody (mAb) Therapy |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: IV Infusion |
|
FREQUENCY: Every three weeks for six doses, then every six weeks
|
Length of infusion: About 30 mins |
FOR MORE INFORMATION: |
Related drugs
